KalVista Pharmaceuticals, Inc. 8-K

What Happened

• On April 29, 2026, KalVista Pharmaceuticals, Inc. announced it entered into an Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. (Parent) and Skyline Merger Sub, Inc. (Purchaser). Under the agreement, Purchaser will commence a cash tender offer to acquire all outstanding KalVista shares (other than excluded or dissenting shares) for $27.00 per share.
• The Offer must begin no later than 10 business days after the Merger Agreement date and will expire 20 business days after commencement unless extended. The deal is not conditioned on financing. If the Offer is successful, Purchaser will merge into KalVista, leaving KalVista as a wholly owned subsidiary of Chiesi.
• The KalVista board has approved the Merger Agreement, determined the transaction is fair and in the best interest of stockholders, and recommends that stockholders tender their shares. A joint press release was filed as Exhibit 99.1.

Key Details

• Offer price: $27.00 per share in cash.
• Timing: Merger Agreement dated April 29, 2026; Offer to commence within 10 business days and run 20 business days (unless extended).
• Closing conditions: Requires valid tenders exceeding 50% of outstanding shares (one more than 50%), HSR waiting period expiration, German and Italian regulatory clearances, customary reps/warranties and no Material Adverse Effect. The transaction is not subject to a financing condition.
• Equity treatment & fees: In-the-money stock options will vest and be cashed out for the spread (Merger Consideration minus exercise price); options at-or-above $27 will be cancelled without payment; RSUs will vest and be cashed out at $27 per share. Termination fee payable by KalVista in certain circumstances: $66,400,000.

Why It Matters

• If completed, the transaction will take KalVista private as a wholly owned subsidiary of Chiesi and deliver $27.00 per share in cash to participating stockholders. The board’s recommendation makes tendering more likely, but the deal still requires shareholder tender levels and multiple regulatory approvals, so timing and completion are not guaranteed.
• The cash-out treatment of options and RSUs affects employees and equity holders (vest-and-pay for in‑the‑money awards; cancellation for out-of-the-money options). Investors should review the forthcoming Offer materials (Schedule TO) and the company’s Solicitation/Recommendation Statement (Schedule 14D-9) for full details and consider regulatory and tender conditions before making decisions.